A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma

Table 1

Background information on US FDA-approved PD-1/PD-L1 inhibitors for the treatment of urothelial carcinoma.

Target	Generic name	Antibody class	Trade name	Development name(s)	Company	Recommended dose and schedule	Date of approval
PD-1	Nivolumab	Human IgG4	Opdivo	BMS-936558, MDX-1106, ONO-4538	Bristol-Myers Squibb Co.	240 mg, every 2 weeks	2 Feb. 2017
	Pembrolizumab	Humanized IgG4	Keytruda	MK-3475, lambrolizumab	Merck and Co. Inc.	200 mg, every 3 weeks	18 May 2017
PD-L1	Atezolizumab	Human IgG1k	Tecentriq	MPDL3280A, RG7446	Genentech Inc.	1200 mg, every 3 weeks	18 May 2016
	Durvalumab	Humanized IgG1k	Imfinzi	MEDI-4736	AstraZeneca UK Limited	10 mg/kg, every 2 weeks	1 May 2017
	Avelumab	Human IgG1	Bavencio	MSB0010718C, MSB0010682	EMD Serono Inc.	10 mg/kg, every 2 weeks	9 May 2017

All are for the patients with locally advanced or metastatic urothelial carcinoma and who has the prior platinum-based chemotherapy.